Creation and verification of an RP-UHPLC technique for abemaciclib and associated impurities in formulations and APIs using Box-Behnken design

Kalpana Krishnaraju; Malarkodi  Velraj

doi:10.69857/joapr.v14i4.2330

Authors

Kalpana Krishnaraju Departments of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Chennai, Tamil Nadu, India- 600117
Malarkodi Velraj Department of Pharmacognosy, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Chennai, Tamil Nadu, India- 600117

DOI:

https://doi.org/10.69857/joapr.v14i4.2330

Keywords:

Abemaciclib, Process-related impurities, Degradants, Forced degradation, Formulation, DoE

Abstract

Background: Strict impurity profiling is necessary to ensure the safety, effectiveness, and regulatory compliance of Abemaciclib (AbB), a selective CDK4/6 inhibitor frequently used in breast cancer treatment. However, a lack of thorough impurity separation, lengthy run times, and low sensitivity are common problems with current analytical techniques. Methodology: A novel reverse-phase ultra-high-performance liquid chromatography (RP-UHPLC) method was developed using a Quality by Design (QbD) framework. Critical method parameters, including mobile phase pH, flow rate, and column temperature, were optimized using Box-Behnken Design (BBD). Chromatographic separation was achieved on a C18 column using an isocratic mobile phase consisting of acetonitrile (40:60, v/v) and ammonium formate buffer (pH 2.7). The technique was validated in accordance with the ICH Q2(R1) requirements. Results and Discussion: The optimized method demonstrated exceptional linearity over the range of 0.02–150 μg/mL (R² > 0.999) with excellent precision (RSD < 2% for AbB and < 10% for related impurities) and showed acceptable accuracy, with mean recoveries ranging from 92.76% to 102.88% across AbB and its related impurities. The detection and quantification limits for AbB were 0.01 μg/mL and 0.02 μg/mL, respectively. Forced degradation studies that effectively distinguished degradation products in oxidative, acidic, and alkaline settings confirmed the method's stability-indicating nature. The 8-minute run time allowed for quick examination. The integration of BBD-based QbD significantly enhanced method robustness, resolution, and sensitivity compared to conventional chromatographic approaches, allowing simultaneous quantification of AbB and its related impurities. Conclusion: For routine quality control, stability investigations, and regulatory-compliant impurity profiling of Abemaciclib, the developed RP-UHPLC method is quick, sensitive, reliable, and appropriate.

Downloads

Download data is not yet available.

References

Smyth EN, Beyre J, Saverno KR, Hadden E, Abedtash H, DeLuca A, et al. Real-world patient characteristics, utilization patterns, and outcomes of US patients with HR+, HER2− metastatic breast cancer treated with abemaciclib. Drugs Real World Outcomes, 9(4), 681–693 (2022) https://doi.org/10.1007/s40801-022-00327-1

Gao HF, Lin YY, Zhu T, Ji F, Zhang LL, Yang CQ, et al. Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: a meta-analysis of randomized clinical trials. Breast, 59, 165–175 (2021) https://doi.org/10.1016/j.breast.2021.07.002

Zhang M, Song J, Guo S, Jin F, Zheng A. Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and meta-analysis. Endocr Relat Cancer, 30(8), e220365 (2023) https://doi.org/10.1530/ERC-22-0365

Cazzaniga ME, Ciaccio A, Danesi R, Duhoux FP, Girmenia C, Zaman K, et al. Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project. Front Oncol, 13, 1247270 (2023) https://doi.org/10.3389/fonc.2023.1247270

Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol, 35(25), 2875–2884 (2017) https://doi.org/10.1200/JCO.2017.73.7585

Kent JA, Bommaraju TV, Barnicki SD, editors. Handbook of Industrial Chemistry and Biotechnology. Springer (2017) https://doi.org/10.1007/978-3-319-52287-6

Usha Rani N, Prasad Rao PTSRK, Ramanjaneyulu K. QbD assisted green and white analytical UPLC method quantification of pharmacopeia impurities of pravastatin in bulk drug and pharmaceutical formulations. J Appl Pharm Res, 14(2), 254–268 (2026) https://doi.org/10.69857/joapr.v14i2.1875

Maithani M, Dwivedi DK. RP-HPLC method development and validation for determination of abemaciclib in bulk drug substance and pharmaceutical dosage forms. J Biomed Pharm Res, 12(5), 31–35 (2023) https://doi.org/10.32553/jbpr.v12i5.1027

Alanazi S. Recent advances in liquid chromatography-mass spectrometry (LC-MS) applications in biological and applied sciences. Anal Sci Adv, 6(1), e70024 (2025) https://doi.org/10.1002/ansa.70024

Ni R, Du X, Huang R, Wu W, Xu J, Ma X, et al. Development and validation of a reversed-phase high-performance liquid chromatography–ultraviolet method for abemaciclib-related substance detection in bulk drugs. J Sep Sci, 45(22), 4070–4078 (2022) https://doi.org/10.1002/jssc.202200551

Margaryan T, Elliott M, Sanai N, Tovmasyan A. Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS/MS. J Pharm Anal, 12(4), 601–609 (2022) https://doi.org/10.1016/j.jpha.2022.05.003

Poetto AS, Posocco B, Zanchetta M, Gagno S, Orleni M, Canil G, et al. A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring. J Chromatogr B, 1207, 123403 (2022) https://doi.org/10.1016/j.jchromb.2022.123403

Yu IT. Factor screening with modified one-factor-at-a-time experiments. Commun Stat Simul Comput, 53(9), 4449–4463 (2024) https://doi.org/10.1080/03610918.2022.2154793

Park G, Kim MK, Go SH, Choi M, Jang YP. Analytical quality by design (AQbD) approach to the development of analytical procedures for medicinal plants. Plants, 11(21), 2960 (2022) https://doi.org/10.3390/plants11212960

Alluri NR, Bandlamudi MR, Kuppusamy S, Morais SR. Implementation of the QbD approach to the analytical method development and validation for the estimation of the treprostinil injection dosage form by RP-HPLC. ACS Omega, 10(17), 17827–17835 (2025) https://doi.org/10.1021/acsomega.5c00373

Elkady EF, Fouad MA, Mozayad AN. Application of Box-Behnken experimental design and response surface methodology for selecting the optimum RP-HPLC conditions for the simultaneous determination of methocarbamol, indomethacin and betamethasone in their pharmaceutical dosage form. BMC Chem, 16(1), 114 (2022) https://doi.org/10.1186/s13065-022-00908-9

Handbook of Analytical Quality by Design. Elsevier (2021) https://doi.org/10.1016/C2019-0-01419-7

Kolla S, Vallabhaneni MR, Puttagunta S, Chakka V. Dual organic modifier, solid core technology and quality by design-based tripartite synergistic model for development and validation of stability indicating method by reverse phase-high performance liquid chromatography for assay and impurities of etoricoxib tablets. Indian J Pharm Sci, (2022) https://doi.org/10.36468/pharmaceutical-sciences.964

Dhangar KR, Jagtap RB, Surana SJ, Hirkhedkar AA. Impurity profiling of drugs towards safety and efficacy: theory and practice. J Chil Chem Soc, 62(2) (2017) https://doi.org/10.4067/S0717-97072017000200024

Passerine BFG, Breitkreitz MC. Important aspects of the design of experiments and data treatment in the analytical quality by design framework for chromatographic method development. Molecules, 29(24), 6057 (2024) https://doi.org/10.3390/molecules29246057

Gandu S, Gandla K. Development of a quality by design-based ultra-performance liquid chromatography method for the simultaneous estimation of casirivimab and imdevimab with greenness metrics. Green Anal Chem, 13, 100248 (2025) https://doi.org/10.1016/j.greeac.2025.100248

Ahmed F, Eticha T, Hymete A, Ashenef A. Principles and applications of ultra-high-performance liquid chromatography. In: High Performance Liquid Chromatography — Recent Advances and Applications. IntechOpen (2023) https://doi.org/10.5772/intechopen.110540

P N S Syamala, Adikay S. A QbD-based stability-indicating RP-HPLC method for larotrectinib: degradation kinetics and integrated white, green, and blue analytical assessment. J Appl Pharm Res, 13(4), 143–161 (2025) https://doi.org/10.69857/joapr.v13i4.1436

Pathak VK, Chandra P, Singh B. Development and validation of a robust QbD-guided (RP-HPLC) analytical technique for quantifying coenzyme Q10 in pharmaceutical dosage form. J Appl Pharm Res, 13(5), 271–286 (2025) https://doi.org/10.69857/joapr.v13i5.1696

Martínez-Chávez A, Tibben MM, de Jong KA, Rosing H, Schinkel AH, Beijnen JH. Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC–MS/MS. J Pharm Biomed Anal, 203, 114225 (2021) https://doi.org/10.1016/j.jpba.2021.114225